Citigroup Inc. Has $2.70 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Citigroup Inc. raised its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 486.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 68,479 shares of the company’s stock after purchasing an additional 56,809 shares during the period. Citigroup Inc. owned approximately 0.21% of Dianthus Therapeutics worth $2,695,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics by 13.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock valued at $64,620,000 after buying an additional 196,117 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Dianthus Therapeutics by 626.4% during the third quarter. JPMorgan Chase & Co. now owns 68,124 shares of the company’s stock worth $2,681,000 after acquiring an additional 58,746 shares in the last quarter. Candriam S.C.A. grew its stake in Dianthus Therapeutics by 25.3% in the third quarter. Candriam S.C.A. now owns 301,428 shares of the company’s stock valued at $11,861,000 after acquiring an additional 60,852 shares during the period. Bessemer Group Inc. grew its stake in Dianthus Therapeutics by 7.8% in the third quarter. Bessemer Group Inc. now owns 16,134 shares of the company’s stock valued at $635,000 after acquiring an additional 1,170 shares during the period. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Dianthus Therapeutics in the third quarter worth about $231,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Up 6.1%

Shares of NASDAQ DNTH opened at $65.20 on Friday. The business’s 50 day moving average price is $48.42 and its two-hundred day moving average price is $40.53. The company has a market cap of $2.82 billion, a PE ratio of -18.74 and a beta of 1.56. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $65.50.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Wedbush upped their price target on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Jefferies Financial Group lifted their price target on Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright upped their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.63.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.